Danilova et al., 2024 - Google Patents
Hot Melt Extrusion Technology as a Modern Strategy for Improving the Bioavailability of FlavonoidsDanilova et al., 2024
View PDF- Document ID
- 5035824597298716929
- Author
- Danilova A
- Gusev K
- Maimistov D
- Flisyuk E
- Publication year
- Publication venue
- Pharmaceutical Chemistry Journal
External Links
Snippet
The pharmacological activity of flavonoids as potential candidates for the development of drugs based on biologically active substances of plant origin is confirmed by research data. The low bioavailability of flavonoids attributed to poor solubility and absorption in the …
- 229930003935 flavonoid 0 title abstract description 55
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Franco et al. | Supercritical antisolvent process for pharmaceutical applications: A review | |
| Giri et al. | Cellulose and its derivatives for application in 3D printing of pharmaceuticals | |
| Kittikunakorn et al. | Twin-screw melt granulation: Current progress and challenges | |
| CN104379175B (en) | Highly branched α-D- glucans | |
| CA2310847C (en) | Method for producing solvent-free non-crystalline biologically active substances | |
| Yin et al. | Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs | |
| JP2014503470A (en) | Curcuminoid solid dispersion formulation | |
| Zhang et al. | Development of combi-pills using the coupling of semi-solid syringe extrusion 3D printing with fused deposition modelling | |
| Puri et al. | Development of maltodextrin-based immediate-release tablets using an integrated twin-screw hot-melt extrusion and injection-molding continuous manufacturing process | |
| Tomar et al. | Amorphous systems for delivery of nutraceuticals: challenges opportunities | |
| EP3911303A1 (en) | Method for manufacturing a solid administration form and solid administration form | |
| Kulkarni et al. | Application of hot melt extrusion for improving bioavailability of artemisinin a thermolabile drug | |
| WO2017061627A1 (en) | Polyphenol-containing solid composition | |
| Maniruzzaman et al. | Novel controlled release polymer-lipid formulations processed by hot melt extrusion | |
| Forster et al. | Twin-screw melt granulation for oral solid pharmaceutical products | |
| Guns et al. | Upscaling of the hot-melt extrusion process: Comparison between laboratory scale and pilot scale production of solid dispersions with miconazole and Kollicoat® IR | |
| Buyukgoz et al. | Enhanced supersaturation via fusion-assisted amorphization during fdm 3d printing of crystalline poorly soluble drug loaded filaments | |
| Danilova et al. | Hot Melt Extrusion Technology as a Modern Strategy for Improving the Bioavailability of Flavonoids | |
| Islam et al. | Development of nanoparticles for pharmaceutical preparations using supercritical techniques | |
| Azad et al. | Bio-fortification of Angelica gigas Nakai nano-powder using bio-polymer by hot melt extrusion to enhance the bioaccessibility and functionality of nutraceutical compounds | |
| Jennotte et al. | Feasibility study of the use of a homemade direct powder extrusion printer to manufacture printed tablets with an immediate release of a BCS II molecule | |
| Kozakiewicz-Latała et al. | Adjusting the melting point of an Active Pharmaceutical Ingredient (API) via cocrystal formation enables processing of high melting drugs via combined hot melt and materials extrusion (HME and ME) | |
| Patel et al. | Application of 3D printing technology for the development of dose adjustable geriatric and pediatric formulation of celecoxib | |
| Wdowiak et al. | Sweeteners show a plasticizing effect on PVP K30—a solution for the hot-melt extrusion of fixed-dose amorphous curcumin-hesperetin solid dispersions | |
| Corrie et al. | HPMCAS-based amorphous solid dispersions in clinic: a review on manufacturing techniques (hot melt extrusion and spray drying), marketed products and patents |